The Enterprise Value as of September 2024 (TTM) for Arvinas, Inc. (ARVN) is 1.58B

According to Arvinas, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.58B. This represents a change of -17.61% compared to the average of 1.92B of the last 4 quarters.

Arvinas, Inc. (ARVN) Historical Enterprise Value (quarterly & annually)

How has ARVN Enterprise Value performed in the past?

The mean historical Enterprise Value of Arvinas, Inc. over the last ten years is 1.57B. The current 1.58B Enterprise Value has changed 9.98% with respect to the historical average. Over the past ten years (40 quarters), ARVN's Enterprise Value was at its highest in in the December 2021 quarter at 4.23B. The Enterprise Value was at its lowest in in the June 2017 quarter at 0.

Arvinas, Inc. (ARVN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Arvinas, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Arvinas, Inc. (ARVN) Average Enterprise Value

How has ARVN Enterprise Value performed in the past?

The current Enterprise Value of Arvinas, Inc. (ARVN) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Arvinas, Inc. (ARVN) Enterprise Value vs. Peers

How is ARVN’s Enterprise Value compared to its peers?

Arvinas, Inc.’s Enterprise Value is greater than C4 Therapeutics, Inc. (433.86M), greater than Monte Rosa Therapeutics, Inc. (279.81M), greater than Nurix Therapeutics, Inc. (1.55B), greater than Foghorn Therapeutics Inc. (414.87M), greater than Relay Therapeutics, Inc. (1.25B), greater than Stoke Therapeutics, Inc. (589.36M), greater than Pliant Therapeutics, Inc. (700.94M), greater than Black Diamond Therapeutics, Inc. (301.75M), greater than Shattuck Labs, Inc. (118.76M), less than Kymera Therapeutics, Inc. (3.12B), less than Ultragenyx Pharmaceutical Inc. (5.93B), less than Crinetics Pharmaceuticals, Inc. (4.08B), less than Revolution Medicines, Inc. (7.20B), greater than Kura Oncology, Inc. (1.57B), greater than Century Therapeutics, Inc. (151.31M),

Build a custom stock screener for Arvinas, Inc. (ARVN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arvinas, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arvinas, Inc. (ARVN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arvinas, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.